 SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 GLOBE NEWSWIRE -- Calithera Biosciences, Inc. Nasdaq: CALA, a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the compensation committee of the companys board of directors granted three new employees a non-qualified stock option to purchase an aggregate of 53,000 shares of Calitheras common stock, at a per share exercise price of 4.91, the closing trading price on November 30, 2020. One-fourth of the options vest in November 2021, and the balance of the options vest in a series of thirty-six successive equal monthly installments thereafter and were granted pursuant to the Calithera Biosciences, Inc. 2018 Inducement Plan, or Inducement Plan, which was approved by Calitheras board of directors in January 2018 in accordance with Nasdaq Listing Rule 5635c4. The stock options also have a ten-year term and are subject to the terms and conditions of the Inducement Plan and the stock option agreement pursuant to which the options were granted. 